Law360, New York (October 19, 2011, 5:06 PM ET) -- Novo Nordisk A/S filed suit Friday in New Jersey aiming to block Sandoz Inc.'s generic version of diabetes treatment Prandin, the latest broadside in an ongoing feud with generic-drug makers over a patent the U.S. Supreme Court has agreed to scrutinize later this year.
The complaint comes in response to a declaratory suit lodged by Sandoz in Michigan federal court in August over the Prandin patent.
Sandoz “knows that it stands to [gain] significant profits by supporting, promoting and encouraging the infringement” of the patent, according...
Novo Ramps Up Prandin IP Battle With Sandoz Suit
To view the full article, take a free trial now.
